Readoutin 104d
Merz Therapeutics GmbH — Xeomin
Phase 3 primary completion: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Episodic Migraine
Readoutin 104d
Phase 3 primary completion: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.